Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common painkiller combo ease cancer treatment pain?

NCT ID NCT02439034

Symptom relief Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding ketoprofen to standard paracetamol (acetaminophen) can better control pain in patients receiving brachytherapy for cervical or upper airway/digestive tract cancers. Sixty-eight adults were randomly assigned to receive either paracetamol alone or paracetamol plus ketoprofen during and after the procedure. The goal was to see if the combination kept pain below a score of 4 out of 10, four hours after surgery, and to track pain levels throughout recovery at home.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Paracetamol and ketoprofen
What this could lead to
If successful, this could establish a standard pain management protocol for brachytherapy patients, reducing pain and improving quality of life during and after treatment.
What could go wrong
This is a small phase 2 trial with only 68 participants, so results may not apply to all patients. Adding ketoprofen may increase side effects like stomach or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

68 people

The number who actually took part.

Started

Feb 2015

Finished

Oct 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with a uterine cervical cancer or an upper aero-digestive tract cancer * Age ≥ 18 years and ≤ 75 years * Patient who are eligible for brachytherapy treatment associated with or without hospital stay * With operative procedure under general anesthesia to set up the material needed for brachytherapy * Performance status ≤ 2 * Creatinine Clearance ≥ 60 ml/min using Cockcroft equation * No coagulation disorder or anticoagulation therapy at curative dose * Registered with a social security system * Patient having dated and signed an informed consent form before initiation of any study procedures Exclusion Criteria: * Respiratory pathology (SpO2\< 70 %) * Severe undernutrition * Previous hypersensitivity reactions such as bronchospasm, asthma, rhinitis, hives or other allergic reaction to ketoprofen, to acetylsalicylic acid, or other NSAIDs * Previous hemorrhage or gastrointestinal perforation during a previous treatment with NSAID * Gastrointestinal hemorrhage , cerebrovascular hemorrhage or other evolutive hemorrhage * Evolutive peptic ulcer, previous peptic ulcer or recurring hemorrhage (2 or more distinct episodes of hemorrhage or ulcer objectified) * Liver insufficiency * Severe renal insufficiency * Severe heart failure * Treatment with another NSAID, including selective cyclooxygenase-2 inhibitors * Intolerance or hypersensitivity to one of the treatments or excipients * Inability to swallow * Pregnant or breastfeeding woman * Patient under tutorship or guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Upper aerodigestive tract neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia cervical cancer cervical carcinoma Head and Neck Neoplasms upper aerodigestive tract neoplasm Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Upper aerodigestive tract neoplasms Uterine cervical cancer

Contacts and locations

Locations

  • Centre Oscar Lambret

    Lille, 59020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.